

# Locally Advanced Pancreatic Cancer Market - A Global and Regional Analysis: Focus on Route of Administration, Therapy, Country, and Region - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/LFCFE3F76F9BEN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: LFCFE3F76F9BEN

## Abstracts

Locally advanced pancreatic cancer is an aggressive, unresectable, non-metastatic tumour involving major blood vessels or regional lymph nodes. Therapeutic approaches include combination chemotherapy regimens, targeted therapies addressing molecular alterations such as KRAS and BRCA, immuno-oncology interventions, and adjunctive supportive care. Advanced diagnostic techniques, including imaging and biomarker profiling, guide treatment selection and improve patient outcomes. The market consists of pharmaceutical companies, clinical research organisations, and academic institutions collaborating to expand therapeutic options, improve survival rates, and provide better patient care.

## Market Lifecycle Stage

The global locally advanced pancreatic cancer market is in the growth stage, characterised by the increasing adoption of multimodal therapies, including chemotherapy, targeted therapy, and immuno-oncology interventions. Historically, treatment primarily focused on palliative care, but precision medicine and combination regimens are transforming clinical outcomes. Growth is supported by technological advancements, increased research, and development activity, and rising clinical trial participation.

The global locally advanced pancreatic cancer market faces challenges such as poor prognosis and late-stage diagnosis, which limit curative intervention opportunities, along with high treatment costs and the complexity of multimodal therapy regimens.

Nevertheless, ongoing innovation, policy support, and adoption of biomarker-guided strategies are enabling incremental improvements in patient survival and quality of life, positioning the market for long-term growth.

### **Market Segmentation:**

#### Segmentation 1 - By Therapy

Chemotherapy

Targeted Therapy

Immunotherapy

Others

Chemotherapy remains the backbone of treatment for locally advanced pancreatic cancer, with regimens such as gemcitabine-based combinations and FOLFIRINOX widely used to improve survival and tumour response. Targeted therapies are gaining momentum due to their ability to selectively inhibit molecular pathways, including KRAS and BRCA mutations, allowing personalised treatment approaches. Immunotherapy, encompassing checkpoint inhibitors and novel combination agents, is emerging due to growing clinical trial activity and the potential for durable responses. Other adjunct therapies, including anti-angiogenic agents and supportive care medications, are often used alongside primary therapies to enhance efficacy and tolerability.

#### Segmentation 2 - By Route of Administration

Intravenous

Oral

Intravenous administration dominates treatment delivery for locally advanced pancreatic cancer, covering chemotherapy, targeted therapies, and immuno-oncology agents. This route ensures precise dosing, rapid bioavailability, and enhanced tolerability through improved infusion protocols. Oral therapies, including small-molecule targeted agents and supportive medications, are increasingly adopted due to patient convenience,

outpatient feasibility, and integration into combination therapy regimens. Both routes reflect a trend toward personalised, multimodal therapy strategies that balance efficacy, safety, and patient quality of life.

### Segmentation 3 - By Region

North America

Europe

Asia-Pacific

Rest-of-the-World

North America leads the global locally advanced pancreatic cancer market due to advanced oncology research and development, robust clinical infrastructure, early adoption of multimodal therapies, and supportive regulatory frameworks. Europe shows significant growth supported by clinical collaborations, reimbursement policies, and rare cancer initiatives that facilitate access to advanced therapies. Asia-Pacific presents emerging opportunities driven by rising disease incidence, expansion of oncology centres, and increasing adoption of precision medicine. The Rest of the World, including Latin America, the Middle East, and Africa, is gradually growing as healthcare infrastructure improves, patient awareness increases, and access to advanced treatment modalities expands.

### **Demand – Drivers and Limitations**

Demand drivers for the global locally advanced pancreatic cancer market:

Advancements in combination chemotherapy, targeted therapy, and immunology approaches

Increasing R&D investments in oncology therapeutics

Adoption of precision medicine and biomarker-driven treatment strategies

Limitations for the global locally advanced pancreatic cancer market:

Poor prognosis and late-stage diagnosis limit curative interventions

High treatment costs and complex multimodal therapy regimens

### **How can this report add value to an organization?**

**Product/Innovation:** This report provides an in-depth evaluation of therapeutic innovations in locally advanced pancreatic cancer, highlighting combination chemotherapy, targeted therapies, and immuno-oncology candidates under development. It helps research and development teams identify unmet clinical needs, potential molecular targets, and strategic partnerships. By mapping innovation hotspots, clinical trial activity, and precision medicine integration, stakeholders can prioritise high-impact research areas, optimise portfolio planning, and accelerate the translation of novel therapies into clinical practice for improved patient outcomes.

**Growth/Marketing:** The report supports strategic market-entry and expansion planning by analysing regional trends, patient access initiatives, and treatment adoption patterns. Insights into multimodal therapy utilisation, biomarker-driven strategies, and reimbursement frameworks enable organisations to target high-growth regions effectively. This intelligence allows marketing and sales teams to optimise resource allocation and design evidence-based commercialisation strategies, aligning product offerings with emerging clinical needs and evolving therapeutic practices for locally advanced pancreatic cancer.

**Competitive:** Comprehensive benchmarking of leading companies, clinical pipelines, and strategic collaborations provides stakeholders with actionable competitive intelligence. Organisations can identify potential co-development partners, acquisition opportunities, and differentiation strategies in the global locally advanced pancreatic cancer market. Evaluation of competitor positioning, research and development intensity, and therapeutic innovation trends enables strategic planning and strengthens market presence, particularly in chemotherapy, targeted therapy, and immuno-oncology, which are transforming the management of locally advanced pancreatic cancer.

### **Key Market Players and Competitive Landscape**

This report provides a detailed competitive analysis of pharmaceutical and biotechnology companies engaged in developing or commercialising therapeutic

interventions for locally advanced pancreatic cancer. The evaluation is based on clinical-stage activity, market presence, research and development investments, product portfolios, and strategic collaborations. Key players include:

A2 Biotherapeutics Inc.

AbbVie Inc.

Astellas Pharma Inc.

AstraZeneca Plc.

Bristol-Myers Squibb

Eli Lilly and Company

Hoffmann-La Roche

Merck & Co., Inc.

Novartis Pharmaceuticals

The competitive dynamics are shaped by combination chemotherapy, targeted therapy, and immuno-oncology approaches, alongside collaborations between academic institutions, clinical research organisations, and pharmaceutical companies that accelerate drug development and clinical access.

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

This report will be delivered in 7-10 working days.

## Contents

Executive Summary  
Scope of Study  
Definition  
Inclusion and Exclusion Criteria

### **1. GLOBAL LOCALLY ADVANCED PANCREATIC CANCER MARKET: INDUSTRY OUTLOOK**

1.1 Market Overview and Ecosystem  
1.2 Epidemiological Analysis  
    1.2.1 U.S.  
    1.2.2 EU  
        1.2.2.1 Germany  
        1.2.2.2 France  
    1.2.3 Rest-of-the-World  
1.3 Market Trends  
1.4 Clinical Trial Analysis  
1.5 Regulatory Landscape Analysis  
    1.5.1 Legal Requirement and Framework in U.S.  
    1.5.2 Legal Requirement and Framework in E.U.  
    1.5.3 Legal Requirement and Framework in Asia-Pacific  
    1.5.4 Legal Requirement and Framework in Rest-of-the-World  
1.6 Market Dynamics  
    1.6.1 Impact Analysis  
    1.6.2 Market Drivers  
    1.6.3 Market Restraints  
    1.6.4 Market Opportunities

### **2. GLOBAL LOCALLY ADVANCED PANCREATIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, \$MILLION, 2024-2035**

2.1 Oral  
2.2 Intravenous

### **3. GLOBAL LOCALLY ADVANCED PANCREATIC CANCER MARKET, BY THERAPY, \$MILLION, 2024-2035**

- 3.1 Chemotherapy
- 3.2 Targeted Therapy
- 3.3 Immunotherapy
- 3.4 Others

#### **4. GLOBAL LOCALLY ADVANCED PANCREATIC CANCER MARKET, BY REGION, \$MILLION, 2024-2035**

- 4.1 North America
  - 4.1.1 Key Findings
  - 4.1.2 Market Dynamics
  - 4.1.3 Market Sizing and Forecast
    - 4.1.3.1 North America Locally Advanced Pancreatic Cancer Market (by Country)
      - 4.1.3.1.1 U.S.
      - 4.1.3.1.2 Canada
- 4.2 Europe
  - 4.2.1 Key Findings
  - 4.2.2 Market Dynamics
  - 4.2.3 Market Sizing and Forecast
    - 4.2.3.1 Europe Locally Advanced Pancreatic Cancer Market (by Country)
      - 4.2.3.1.1 Germany
      - 4.2.3.1.2 France
      - 4.2.3.1.3 Italy
      - 4.2.3.1.4 Spain
      - 4.2.3.1.5 U.K.
      - 4.2.3.1.6 Rest-of-Europe
- 4.3 Asia-Pacific
  - 4.3.1 Key Findings
  - 4.3.2 Market Dynamics
  - 4.3.3 Market Sizing and Forecast
    - 4.3.3.1 Asia-Pacific Locally Advanced Pancreatic Cancer Market (by Country)
      - 4.3.3.1.1 Japan
      - 4.3.3.1.2 Rest-of-Asia-Pacific
- 4.4 Rest-of-the-World
  - 4.4.1 Key Findings
  - 4.4.2 Market Dynamics
  - 4.4.3 Market Sizing and Forecast

#### **5. GLOBAL LOCALLY ADVANCED PANCREATIC CANCER MARKET:**

## **COMPETITIVE BENCHMARKING AND COMPANY PROFILES**

### 5.1 Competitive Benchmarking

### 5.2 Competitive Landscape

#### 5.2.1 Key Strategies and Developments by Company

##### 5.2.1.1 Funding Activities

##### 5.2.1.2 Mergers and Acquisitions

##### 5.2.1.3 Regulatory Approvals

##### 5.2.1.4 Partnerships, Collaborations, and Business Expansions

#### 5.2.2 Key Developments Analysis

### 5.3 Company Profiles

#### 5.3.1 A2 Biotherapeutics Inc.

##### 5.3.1.1 Company Overview

##### 5.3.1.2 Product Portfolio

##### 5.3.1.3 Target Customers/End Users

##### 5.3.1.4 Key Personnel

##### 5.3.1.5 Analyst View

#### 5.3.2 Abbvie Inc.

##### 5.3.2.1 Company Overview

##### 5.3.2.2 Product Portfolio

##### 5.3.2.3 Target Customers/End Users

##### 5.3.2.4 Key Personnel

##### 5.3.2.5 Analyst View

#### 5.3.3 Astellas Pharma Inc.

##### 5.3.3.1 Company Overview

##### 5.3.3.2 Product Portfolio

##### 5.3.3.3 Target Customers / End Users

##### 5.3.3.4 Key Personnel

##### 5.3.3.5 Analyst View

#### 5.3.4 AstraZeneca Plc.

##### 5.3.4.1 Company Overview

##### 5.3.4.2 Product Portfolio

##### 5.3.4.3 Target Customers / End Users

##### 5.3.4.4 Key Personnel

##### 5.3.4.5 Analyst View

#### 5.3.5 Bristol-Myers Squibb

##### 5.3.5.1 Company Overview

##### 5.3.5.2 Product Portfolio

##### 5.3.5.3 Target Customers/End Users

- 5.3.5.4 Key Personnel
- 5.3.5.5 Analyst View
- 5.3.6 Eli Lilly and Company
  - 5.3.6.1 Company Overview
  - 5.3.6.2 Product Portfolio
  - 5.3.6.3 Target Customers/End Users
  - 5.3.6.4 Key Personnel
  - 5.3.6.5 Analyst View
- 5.3.7 Hoffmann-La Roche
  - 5.3.7.1 Company Overview
  - 5.3.7.2 Product Portfolio
  - 5.3.7.3 Target Customers/End Users
  - 5.3.7.4 Key Personnel
  - 5.3.7.5 Analyst View
- 5.3.8 Novartis Pharmaceuticals
  - 5.3.8.1 Company Overview
  - 5.3.8.2 Product Portfolio
  - 5.3.8.3 Target Customers/End Users
  - 5.3.8.4 Key Personnel
  - 5.3.8.5 Analyst View
- 5.3.9 Merck & Co., Inc.
  - 5.3.9.1 Company Overview
  - 5.3.9.2 Product Portfolio
  - 5.3.9.3 Target Customers/End Users
  - 5.3.9.4 Key Personnel
  - 5.3.9.5 Analyst View
- 5.3.10 Others

## **6. RESEARCH METHODOLOGY**

## List Of Figures

### LIST OF FIGURES

Figure: Locally Advanced Pancreatic Cancer Market (by Scenario), \$Million, 2024, 2030, and 2035

Figure: Global Locally Advanced Pancreatic Cancer Market, 2024 and 2035

Figure: Global Locally Advanced Pancreatic Cancer Market Key Trends, Impact Analysis, 2024-2035

Figure: North America Locally Advanced Pancreatic Cancer Market, \$Million, 2024-2035

Figure: Europe Locally Advanced Pancreatic Cancer Market, \$Million, 2024-2035

Figure: Asia-Pacific Locally Advanced Pancreatic Cancer Market, \$Million, 2024-2035

Figure: Rest-of-the-World Locally Advanced Pancreatic Cancer Market, \$Million, 2024-2035

## List Of Tables

### LIST OF TABLES

Table: Market Snapshot

Table: Market Dynamics

Table: Global Locally Advanced Pancreatic Cancer Market (by Route of Administration), \$Million, 2024-2035

Table: Global Locally Advanced Pancreatic Cancer Market (by Therapy), \$Million, 2024-2035

Table: Global Locally Advanced Pancreatic Cancer Market (by Region), \$Million, 2024-2035

## I would like to order

Product name: Locally Advanced Pancreatic Cancer Market - A Global and Regional Analysis: Focus on Route of Administration, Therapy, Country, and Region - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/LFCFE3F76F9BEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LFCFE3F76F9BEN.html>